The Global Health Body Sounds Warning Over Critical Lack of Weight-Loss Medications
Under one in 10 patients eligible to benefit from GLP-1 drugs including Wegovy can access them, caution the global health agency as it releases its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging increased and just availability to these injectable treatments.
Per estimates, over two billion are projected to be living with obesity by 2030 if no action is taken.
"The new guidance recognises that obesity is a chronic disease that can be managed with holistic and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to universal access to the injections that can aid individuals in losing considerable weight, says the organization.
GLP-1 Therapy Scarcity
Even under the current most favorable case, the production of such drugs could only cover about 100 million people β under 10% of those who need them, according to the WHO.
The recommendation urges governments and firms to widen access, by measures such as patent sharing.
The intellectual property rights on semaglutide β the main ingredient of Novo Nordisk's Wegovy β is due to expire in a number of countries in 2026.
The Way Weight-Loss Drugs Function
The injections mimick a biological compound to reduce digestion speed, reduce hunger and boost satiety so users consume fewer calories.
People commonly begin shedding pounds within a few weeks of beginning the weekly injections.
Research indicates users may put most of the weight back on a year later of discontinuing the treatment, when their normal hunger come back.
To be above a healthy weight raises your chance for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts individuals in all nations and was linked to millions of deaths worldwide in 2024, according to the health agency.
